PDCD1 and non-small cell lung carcinoma: Luckily, PD-1 and PD-L1 were the widely supported biomarkers to guide immunotherapy, and the ICB targeting the two biomarkers has achieved great clinical therapeutic results in NSCLC (Ettinger et al., 2022).